anonymous
Guest
anonymous
Guest
Cry foul about Amgen as much as you want these are businesses to make a profit and provide medicines to patients ....in that order (if you want to be in a different order than you shouldn't be a public company with shareholders) At the end of the day Regeneron has a track record and approach to science that is incomparable in the industry and everyone tries to take shots at them..; they are innovative and creative and . have a big target on their back because of it - they need to pay more attention to IP on the front end to create less risk on the backend for these kind of fiascoes to be possible by competitors. Sanofi should know better as well - they invested 1 billion dollars on Praluent and probably 100 million on lawyers and may not be able to market in the US...thats straight up bad judgement and management. sorry
You give REGN a lot of credit. Where are you getting this info about creative, innovative, etc. I work at REGN and management disciplines employees for being honest, not stealing ideas, documenting cGMP documents correctly, etc. If you try to be ethical, legal, follow a moral path, HR finds you and reviews performance improvement plans.
Unfortunately we employ too many old timers who now hold positions of authority to screw us all. As long as the company shows no competence (e.g., failing at the core business of IP), refuses to listen to experts due to overwhelming HUBRIS, and lack accountability - we're all in the same boat going to FUCKED-VILLE.
As a positive, I attend work everyday anticipating which positive spin our "leaders" communicate...... LOL! Complete BS.
The leadership intentionally skipped reading patent files to complete documents FASTER. Awesome plan morons. Just waiting for my next check while anticipating another comical manager's meeting, LOL.